Date: 2015-03-10
Type of information: Capital increase
Company: Delphi Genetics (Belgium)
Investors: Sambrinvest (Belgium) Invest4 DelphiG2 (Belgium), François Blondel and Dr. Philippe Janssens de Varebeke, the two managing directors of the company, Mr. Michel Milinkovitch and ULB (Université Libre de Bruxelles) through its fund Theodorus (Belgium)
Amount: € 1 million
Funding type: capital increase
Planned used: The funds will be used to support Delphi Genetics\' latest development in “Good Manufacturing Practices (GMP)” services for protein and DNA productions, especially engineered for small/medium scale needs. Based in Gosselies, Delphi Genetics is a spin-off of the ULB (Université Libre de Bruxelles) and develops technologies for DNA and protein productions (including antibodies) by using its unique expertise in the field of plasmid stabilisation systems. Delphi Genetics is involved in several research projects including the use of the Staby® technology for the development of DNA vaccines, the adaptation of the technology to mammalian cells and the development of antibodies. Delphi Genetics also provides custom services in genetic engineering, development and productions of proteins, pDNA and antibodies.
Others: * On March 10, 2015, Delphi Genetics announced the closing of a capital increase in excess of € 1 Million. Equity funds were provided by lead investors Sambrinvest (a venture capital fund active in Charleroi/Thuin area) and Invest4 DelphiG2 (Mr. François Blondel and Dr. Philippe Janssens de Varebeke), together with the two managing directors of the company, Mr. Michel Milinkovitch and ULB (Université Libre de Bruxelles) through its fund Theodorus SCA.
Therapeutic area: Technology - Services
